The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions

Bioequivalence Clinical Trial

— Umifenovir  

Official title:

Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Atafenovir 200 Mg Kapsul In Comparison With Arbidol 100 Mg Kapsul In Healthy Male Subjects Under Fasting Conditions

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04476719
• Other study ID #: NOV2020/01918
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 9, 2020
• Est. completion date: August 20, 2020

Study information

• Verified date: June 2020
• Source: Atabay Kimya Sanayi Ticaret A.S.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single dose of Reference product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride and a single dose of Test product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with Covid-19 Pandemic precautions.

Description:

In order to investigate the bioequivalence of all products, the 90% confidence intervals will be calculated for the geometric mean ratios of test and reference for Cmax and AUC0-tlast of umifenovir. These confidence intervals will then be compared with the corresponding acceptance ranges.

In order to achieve a better approximation to a normal distribution, Cmax and AUC0-tlast data for umifenovir will be logarithmically transformed (base e) before analysis. The sources of variation will be treatments, periods, sequences and subjects within the sequence. Evaluation of treatment, period, sequence and subject (nested within sequence) effects at 5% level of significance will be performed. From the result, the two one-sided hypothesis at the 5% level of significance will be tested by constructing the 90% confidence interval for the geometric mean ratios of test/reference products. The confidence interval is calculated by retransformation of the shortest confidence interval for the difference of the ln-transformed mean values. Differences in tmax will be evaluated non-parametrically.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 18
• Est. completion date: August 20, 2020
• Est. primary completion date: July 22, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Healthy Caucasian male subjects aged between 20 and 40 years,

2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period,

3. Two Negative Covid-19 PCR test results.

4. Negative alcohol breath test results,

5. Normal physical examination at screening visit,

6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,

7. Ability to communicate adequately with the investigator himself or his representatives,

8. Ability and agreement to comply with the study requirements,

9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,

10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,

11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),

12. Understanding of the study and agreement to give a written informed consent.

Exclusion Criteria:

1. Who have atopic constitution or asthma or known allergy for umifenovir and/or any other ingredients of the products.

2. Who have positive Covid-19 PCR test result.

3. Any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.

4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator),

5. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.

6. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.

7. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.

8. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).

9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.

10. History of allergic response to heparin.

11. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.

12. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.

13. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study.

14. History of drug abuse.

15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).

16. Positive blood test for HBV, HCV and HIV.

17. Who have relationship to the investigator.

18. Who are not suitable to any of inclusion criteria.

19. History of difficulty of swallowing.

20. Intake of depot injectable solutions (including study medications) within 6 months before start of the study.

21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.

22. Special diet due to any reason, e.g. vegetarian.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• ATAFENOVIR 200 MG KAPSUL
A 200 mg capsule 0ral administration with 240 ml water
• ARBIDOL 100 MG KAPSUL
Two 100 mg capsules will be administrated with 240 ml water orally.

Locations

Country	Name	City	State
Turkey	Novagenix Drug R&D Center	Akyurt	Ankara
Turkey	Farmagen Ar-Ge Biyot. Ltd. Sti.	Sahinbey	Gaziantep

Sponsors (3)

Lead Sponsor	Collaborator
Atabay Kimya Sanayi Ticaret A.S.	Farmagen Ar-Ge Biyot. Ltd. Sti, Novagenix Bioanalytical Drug R&D Center

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary PK Endpoint	AUC0-tlast umifenovir	12 weeks
Primary	Primary PK Endpoint	Cmax of umifenovir	13 weeks
Secondary	Secondary PK Endpoint	t1/2 of umifenovir	14 weeks
Secondary	Secondary PK Endpoint	tmax of umifenovir	15 weeks
Secondary	Secondary PK Endpoint	AUC0-inf of umifenovir	16 weeks